Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

772 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG. Siu LL, et al. Among authors: von hoff dd. Clin Cancer Res. 2002 Jul;8(7):2157-66. Clin Cancer Res. 2002. PMID: 12114416 Clinical Trial.
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK. Hammond LA, et al. Among authors: von hoff dd. Clin Cancer Res. 2004 Mar 1;10(5):1645-56. doi: 10.1158/1078-0432.ccr-03-0174. Clin Cancer Res. 2004. PMID: 15014015 Clinical Trial.
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlefield D, Burris HA, Von Hoff DD, Rowinsky EK. Eckhardt SG, et al. Among authors: von hoff dd. Clin Cancer Res. 1998 Mar;4(3):595-604. Clin Cancer Res. 1998. PMID: 9533526 Clinical Trial.
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. Among authors: von hoff dd. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD. Rowinsky EK, et al. Among authors: von hoff dd. J Clin Oncol. 1998 Sep;16(9):2964-76. doi: 10.1200/JCO.1998.16.9.2964. J Clin Oncol. 1998. PMID: 9738565 Clinical Trial.
772 results